FDA Fast-Tracks Psychedelic Treatments for Depression, PTSD

The path to new mental health treatments just got a lot shorter for millions of Americans.

The Food and Drug Administration announced Friday it's fast-tracking the review process for three companies studying psychedelic compounds as treatments for depression and post-traumatic stress disorder. The move could bring relief to people who haven't responded to traditional therapies.

Two companies are investigating psilocybin, the active compound in magic mushrooms, as a treatment for depression that resists standard medications and for major depressive disorder. A third company is studying methylone, a molecule similar to MDMA, as a potential PTSD treatment.

The announcement follows an executive order from President Trump directing the FDA to speed up development and approval of psychedelic therapies. Health and Human Services Secretary Robert F. Kennedy Jr. emphasized the urgent need for new options during a Senate hearing Wednesday.

"We are accelerating the research, approval, and responsible access to promising mental health treatments to confront our nation's mental health crisis head-on, especially for our veterans," Kennedy said in a statement.

The FDA will prioritize treatments showing early evidence they work better than existing therapies for mental health conditions. Psilocybin has shown promise in several clinical trials for treating depression, though research is still in relatively early stages.

The agency also approved a phase 1 clinical trial for noribogaine hydrochloride, a form of ibogaine, to treat alcohol use disorder. The drug has been extremely difficult to study in the U.S. because it's classified as Schedule I, but preliminary trials suggest it may help with substance use disorders.

The Ripple Effect

The fast-track designation means these therapies could reach patients years sooner than through traditional approval pathways. For the estimated 16 million American adults who experience major depression each year, and the millions more living with PTSD, this represents a potential breakthrough.

Transcend Therapeutics, developing the PTSD treatment, received "breakthrough therapy" designation in 2025, putting it on an even faster path to FDA review. While phase 3 trials confirming safety and effectiveness haven't been completed yet, the early results have been promising enough to warrant expedited attention.

Veterans groups have been particularly vocal advocates for psychedelic therapy research, citing the urgent need for effective PTSD treatments. Now that research is moving forward with federal support.

This marks a significant shift in how the medical community approaches both psychedelics and treatment-resistant mental health conditions, opening doors that seemed firmly closed just a few years ago.